Pharmacy Podcast Network

Belkins
In March of 2009, Institutional Pharmacy Technology marketing leader, Todd S. Eury, launched the Pharmacy Podcast Show. Over the years, the Pharmacy Podcast has accumulated over 67,000+ listeners and subscribers and is the most popular and downloaded podcast about the Pharmacy Industry. The Pharmacy Podcast Show transformed into the Pharmacy Podcast Network (PPN) in 2016 and will continue to collect the thought leading interviews with some of the most brilliant minds in Pharmacy with over 25 co-hosts. The PPN is a Digital Health Publication and Content Developing partner to the Pharmaceutical industry focusing on Specialty medications, pharmacy business supportive technologies, and industry trends. The PPN is dedicated to Specialty, Retail, Long-term Care, Micro-Chain, – Pharmacy Businesses, Patients, and Pharmacy Students with special content for each of these specific audiences. The PPN is the nation's largest network of podcasts dedicated to the pharmacy professional and industry insiders leading with our 25 co-hosts interviewing dynamic people in the pharmacy industry making a difference for our profession, customers, and patients. The definition of “Innovation” is: A new method, idea, product, or process. Processing, implementing, operating, or designing beyond the status-quo.

Related News

ANTI-PARASITIC DRUG SAID TO 'KILL' COVID-19 CELLS

Alcoholics Anonymous | April 09, 2020

news image

Scientists in Australia have found that an anti-parasitic drug available on the market “can kill” the growing cell culture of the deadly coronavirus within 48 hours. However, researchers say the drug cannot be used in humans for COVID-19 until further testing and clinical trials prove its safety and effectiveness. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 [COVID-19] virus growing in cell culture,” said a statement by Melbourn...

Read More

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

news image

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

BUSINESS INSIGHTS

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC | September 21, 2021

news image

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

PHRMA, BIO CAMPAIGN CHAMPIONS MEMBERS' DETERMINATION TO BEAT COVID-19

FiercePharma | March 23, 2020

news image

Together is better, especially when it comes to fighting COVID-19. That’s how pharma and biotech companies are working—and the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade groups want everyone to know. They've launched a co-sponsored print and digital campaign titled “Our Commitment to Beat Coronavirus” that lays out the six key steps biopharma companies are taking to combat the novel coronavirus. Tho...

Read More

Alcoholics Anonymous | April 09, 2020

news image

ANTI-PARASITIC DRUG SAID TO 'KILL' COVID-19 CELLS

Scientists in Australia have found that an anti-parasitic drug available on the market “can kill” the growing cell culture of the deadly coronavirus within 48 hours. However, researchers say the drug cannot be used in humans for COVID-19 until further testing and clinical trials prove its safety and effectiveness. “Scientists showed that a single dose of the drug, Ivermectin, could stop the SARS-CoV-2 [COVID-19] virus growing in cell culture,” said a statement by Melbourn...

Read More

BUSINESS INSIGHTS

Glaukos | September 20, 2021

news image

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

BUSINESS INSIGHTS

Hikma Pharmaceuticals PLC | September 21, 2021

news image

HIKMA AND FAES FARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR THE COMMERCIALISATION OF BILASTINE TABLETS IN THE US

Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, announces the signing of an exclusive US license agreement with FAES Farma S.A. to commercialise Bilastine tablets, a non-sedating second generation antihistamine molecule for the treatment of allergic rhinitis and urticaria. Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercial...

Read More

FiercePharma | March 23, 2020

news image

PHRMA, BIO CAMPAIGN CHAMPIONS MEMBERS' DETERMINATION TO BEAT COVID-19

Together is better, especially when it comes to fighting COVID-19. That’s how pharma and biotech companies are working—and the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade groups want everyone to know. They've launched a co-sponsored print and digital campaign titled “Our Commitment to Beat Coronavirus” that lays out the six key steps biopharma companies are taking to combat the novel coronavirus. Tho...

Read More